22nd Century Group, Inc. (XXII)

Over the past six months, 22nd Century Group's stock has experienced significant volatility and a substantial decline. Key events impacting the stock include the Q3 2025 earnings report with net revenue of $4 million and a gross profit of -$1.1 million, the Q2 2025 earnings report with an EPS of -$197.40, a 1-for-15 reverse stock split on January 22, 2026, and the filing for VLN® MRTP renewal on January 6, 2026. XXII underperformed the US Tobacco industry and the US Market over the past year.

The provided information does not explicitly detail seasonal patterns in demand for 22nd Century Group's products and services. The company plans its production to align with its projections rather than being overtly driven by distinct seasonal consumer purchasing habits.

22nd Century Group, Inc. is an agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science. The company operates within the Tobacco sector and has ties to the Biotechnology, Life Sciences, and AgTech industries. Its major products include VLN® reduced nicotine content cigarettes, SPECTRUM research cigarettes, and contract manufacturing services. The company also develops proprietary plants with optimized alkaloid and flavonoid profiles, as well as improved yields and valuable agronomic traits in hemp/cannabis and hop plants.

Headquartered in Mocksville, North Carolina, 22nd Century Group has a growing presence across the United States. It has launched VLN® products in pilot programs in Chicago and Colorado and has regulatory authorizations to sell VLN® in 40 states and the District of Columbia. Globally, the company leverages over 129 issued patents across 78 countries and is exploring international launch programs in Asia and Europe.

22nd Century Group's brand reputation is shaped by its pioneering work in tobacco harm reduction and its unique regulatory achievements, including having the only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product. The company's financial performance, including significant stock price declines and missed earnings estimates, could negatively impact its reputation among investors and in the broader financial community.

22nd Century Group, Inc. has 34 institutional owners and shareholders, holding a total of 302,679 shares as of February 3, 2026. Major institutional owners include DRW Securities, LLC, Anson Funds Management LP, and Vanguard Group Inc. Institutional holders are a mix of high-risk hedge funds and specialized institutional players, alongside a large retail investor base.